SUN-189 Linear Growth and Metabolic Outcomes of Growth Hormone Treatment in Childhood-Onset Craniopharyngioma: The OUTSPREAD Study

Abstract Disclosure: S. Kim: None. S. Cho: None. Y. Lee: None. S. Chang: None. J. Moon: None. J. Kim: None. Y. Lee: None. Y. Lee: None. M. Ahn: None. J. Suh: None. Objective: To investigate changes in growth status and metabolic parameters before and after growth hormone (GH) treatment for patients with craniopharyngioma. Methods: This restrospective study included 134 patients (80 males and 54 females) with craniopharyngoma from the multicenter study for Ideal Outcomes of Pediatric Rare Endocrine and Metabolic Diseases in Korea (OUTSPREAD study), with available data on growth status and metabolic parameters before and after growth hormone treatment. Patients who received treatment for ≥1 year were included. Auxological and biochemical data from at diagnosis, at the start of GH, 1 year, 2 years, and 3 years after GH treatment, and at GH discontinuation were collected. Results: The mean age at craniopharyngioma diagnosis was 7.6 ± 3.5 years, GH treatment was initiated at 9.4 ± 3.5 years, and the mean age at the end of GH treatment was 15.7 ± 2.2 years. Before growth hormone treatment, height and weight were below average (standard deviation score: -1.78 ± 1.50 and -0.24 ± 1.57, respectively), while body mass index (BMI) was above average (0.99 ± 1.43). After treatment, height and weight significantly increased while BMI decreased (p<0.01 for all) . Aspartate aminotransferase levels (IU/L) significantly decreased after 1 and 2 years of treatment (baseline: 35.9 ± 23.0; 1st year: 27.8 ± 10.5, p<0.01; second year: -27.9 ± 10.9, p=0.04), as did alanine aminotransferase levels (IU/L) after 1 year of treatment (baseline: 28.9 ± 37.3; 1st year: 20.8 ± 20.9, p<0.01). Total cholesterol levels (mg/dL) significantly decreased following 1, 2, and 3 years of treatment (baseline: 186.8 ± 35.0; 1st year: 175.1 ± 30.8; 2nd year: 172.2 ± 43.3; 3rd year: -177.2 ± 43.3, p<0.01 for all). Low density lipoprotein-cholesterol (mg/dL) also significantly improved after 1 year of treatment (baseline: 123.9 ± 33.6; 1st year: 106.4 ± 34.7, p=0.04). Random glucose levels increased slightly and glycosylated hemoglobin levels remained stable. Conclusions: This study is the first longitudinal report demonstrating that growth hormone treatment has positive effects on growth and metabolic parameters in Korean patients treated for craniopharyngioma. Presentation: Sunday, July 13, 2025